Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson (JNJ) reported Q3 revenue of $25.9B and EPS of $2.59, beating estimates, but shares fell 6% due to weak medical device sales. The company raised its 2026 sales and earnings guidance. JNJ's medical tech division, about 1/3 of total sales, underperformed, with CEO hinting at a potential spinoff of its orthopedics business. Despite this, JNJ's oncology business grew 16% YoY, driven by key drugs like Darzalex, Rybrevant, and Tecvayli.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are offset by a weaker‑than‑expected med‑tech segment, causing a 6% share decline.
Market read
Large‑cap earnings with mixed signals; short‑term sell‑off but long‑term growth narrative remains intact.
What to watch
Oncology pipeline momentum and a 2% dividend yield provide defensive appeal despite short‑term med‑tech concerns.
Background
Johnson & Johnson reported Q3 2026 results, beating revenue and EPS expectations and raising full‑year guidance.
Ticker impact
Q3 earnings beat estimates and raised full-year sales guidance, but shares fell ~6% on med‑tech weakness.
likely downward pressure as the market prices in the med‑tech disappointment.
Guidance was raised, but the unexpected med‑tech miss triggered a sell‑off; the move was sizable and immediate.
Market effects
MedTech segment may see broader scrutiny, potentially weighing on other health‑care stocks.
U.S. market sentiment could dip slightly as a large‑cap health‑care name underperforms.
Limited to U.S. equities; no immediate global macro effect.
Counterpoint
The dip may present a buying opportunity given the strong overall earnings and long‑term oncology growth.
Key entities
- companyJohnson & Johnson
U.S. health‑care conglomerate (ticker JNJ).
- business unitDePuy Synthes
JNJ's orthopedics division under consideration for spinoff.
